Related Experiment Video

Updated: Jul 16, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Biological therapies: new treatment options for ANCA-associated vasculitis?

Peer M Aries1, Peter Lamprecht, Wolfgang L Gross

  • 1University Hospital Schleswig-Holstein, Campus Luebeck, Department of Rheumatology and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Lübeck, Germany. Rheumatologie@hamburg.de

Expert Opinion on Biological Therapy
|March 22, 2007
PubMed

Insights

Biological therapies show promise for vasculitis, particularly antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. While some treatments like TNF-alpha blockers and rituximab have shown benefits, long-term safety and efficacy require further evaluation.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Biological therapies offer targeted immune modulation.
  • Previous studies on TNF-alpha blockers in systemic vasculitis yielded mixed results.
  • Limited data exist on the efficacy of biologics in specific vasculitis subtypes.

Purpose of the Study:

  • To review recent data on biological therapies in vasculitis.
  • To evaluate the clinical utility of biologics in various vasculitis types.
  • To appraise current knowledge on biologic use in vasculitis management.

Main Methods:

  • Literature review of recent studies on biologicals in vasculitis.
  • Analysis of clinical trial data and case series.
  • Synthesis of evidence regarding efficacy and safety.

Main Results:

  • TNF-alpha blockers show potential in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.
  • Rituximab's efficacy is clear in ANCA-associated vasculitis, but less so in granulomatous Wegener's.
  • Interferon-alpha has shown short-term benefits but long-term side effects in Churg-Strauss syndrome.

Conclusions:

  • Biologicals represent a significant advancement in vasculitis treatment.
  • Careful patient selection and monitoring are crucial for optimal outcomes.
  • Further research is needed to clarify long-term safety and efficacy profiles.

More Related Videos

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...